| Potential biomarkers of temporomandibular joint disorders. | |
| | |
MedLine Citation:
|
PMID: 21163381 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: The purpose of this study was to identify protein markers present in subjects with temporomandibular joint disorders (TMDs) and clicking compared with the levels in controls. MATERIALS AND METHODS: This was a pilot case-control study, and we report the preliminary results. Samples of joint aspirate collected from patients with TMDs and controls who had undergone surgery for a problem other than TMDs were analyzed using isobaric tags for relative and absolute quantitation (iTRAQ) and biotin-labeled-based protein arrays. The data obtained from these techniques were used to identify the proteins of interest, which were then quantitated using enzyme-linked immunosorbent assay (ELISA). The patient samples studied included joint aspirate collected clinically from the controls and patients and included samples from both the right and the left sides of each patient with a TMD. RESULTS: The 8 TMJ aspirate samples from 6 subjects included 5 aspirate samples from 4 patients and 3 from 2 controls. The greatest standardized protein concentration of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 (EG-VEGF/PK1) and D6 was found in both joints of the controls compared with the levels from the joints of the patients. With 1 exception, the standardized protein concentration was significantly lower in the patients than in the controls. The lower levels of EG-VEGF/PK1 and D6 in the patients compared with the controls suggest that these cytokines might be possible biomarkers for TMDs. CONCLUSION: In the present pilot study, greater levels of EG-VEGF/PK1 and D6 were found in the controls than in the patients with TMDs. Proteomic analysis of the proteins present in the diseased joints compared with those in the controls might help to identify proteins present when pain or degeneration of the joint occurs. The proteomic information might be useful in the development of future therapies. |
| | |
Authors:
|
Megan M Herr; Kristin M Fries; L George Upton; Laura E Edsberg |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons Volume: 69 ISSN: 1531-5053 ISO Abbreviation: J. Oral Maxillofac. Surg. Publication Date: 2011 Jan |
Date Detail:
|
Created Date: 2010-12-17 Completed Date: 2011-02-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8206428 Medline TA: J Oral Maxillofac Surg Country: United States |
Other Details:
|
Languages: eng Pagination: 41-7 Citation Subset: AIM; D; IM |
Copyright Information:
|
Copyright © 2011 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved. |
Affiliation:
|
Natural Sciences Department, Daemen College, Amherst, NY, USA. Megan_Herr@urmc.rochester.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Activins
/
analysis Adolescent Adult Biological Markers / analysis* Carbonic Anhydrases / analysis Case-Control Studies Chemokine CCL21 / analysis Dislocations / diagnosis, metabolism Female Humans Insulin-Like Growth Factor II / analysis Matrix Metalloproteinase 16 / analysis Paracentesis Peroxiredoxins / analysis Pilot Projects Protein Array Analysis Proteome / analysis* Receptors, CCR10 / analysis Synovial Fluid / chemistry Temporomandibular Joint Disk / pathology Temporomandibular Joint Disorders / diagnosis*, metabolism Vascular Endothelial Growth Factor, Endocrine-Gland-Derived / analysis Young Adult alpha-Globins / analysis beta-Globins / analysis gamma-Globins / analysis |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/CCL21 protein, human; 0/Chemokine CCL21; 0/MMP16 protein, human; 0/Proteome; 0/Receptors, CCR10; 0/Vascular Endothelial Growth Factor, Endocrine-Gland-Derived; 0/activin A; 0/activin B; 0/alpha-Globins; 0/beta-Globins; 0/chemokine receptor D6; 0/gamma-Globins; 104625-48-1/Activins; 67763-97-7/Insulin-Like Growth Factor II; EC 1.11.1.15/PRDX2 protein, human; EC 1.11.1.15/Peroxiredoxins; EC 3.4.24.-/Matrix Metalloproteinase 16; EC 4.2.1.1/Carbonic Anhydrases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel soybean/gelatine-based bioactive and injectable hydroxyapatite foam: Material properties and c...
Next Document: Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors.